Skip to main
RZLT
RZLT logo

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 69%
Buy 31%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute Inc's incremental growth in research and development (R&D) expenses of 4.9% year-over-year, aligning closely with their clinical advancement initiatives, suggests a commitment to innovation and a robust pipeline, particularly with the upcoming Phase 3 study of ersodetug. The company’s narrower-than-expected loss of $0.22 per share in F2Q25, which was better than both internal estimates and market consensus, indicates improved operational efficiency and potential for future profitability. Additionally, the Breakthrough Therapy Designation awarded in January is expected to facilitate quicker patient enrollment in clinical trials, enhancing the likelihood of successful outcomes for its pipeline products RZ358 and RZ402.

Bears say

Rezolute Inc reported a loss per share of $0.27 for fiscal second quarter 2024, indicating a challenging financial position. The enrollment criteria for the sunRIZE Phase 3 study present significant hurdles, including high screen failure rates of 35-40%, which could adversely affect trial outcomes and the overall product pipeline. Additionally, concerns regarding the lower expected placebo response rates may further complicate the analysis and market perception of the company's development efforts, contributing to a cautious outlook for the stock.

Rezolute (RZLT) has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 69% of analysts recommend a Strong Buy, 31% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 13 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.